G6PD and non-autoimmune hemolytic anemia: That flaw threatens the approximately 400 million G6PD-deficient people globally, representing about 8% of people living in malaria endemic countries [3], with a potentially life-threatening acute haemolytic anaemia at therapeutic hypnozoitocidal doses [4].